Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancers Dependent on the Epidermal Growth Factor Receptor Pathway

被引:360
作者
Nguyen, Kim-Son H. [1 ]
Kobayashi, Susumu [1 ]
Costa, Daniel B. [1 ]
机构
[1] Harvard Univ, Div Hematol Oncol, Beth Israel Deaconess Med Ctr, Dept Med,Sch Med, Boston, MA 02215 USA
关键词
BIBW; 2992; D761Y; Gefitinib; ErbB3; Erlotinib; HKI-272; L747S; MET; PF-00299804; T790M; XL647; PROSPECTIVE PHASE-II; GENE COPY NUMBER; GEFITINIB TREATMENT; EGF RECEPTOR; ANTITUMOR-ACTIVITY; TREATED PATIENTS; DRUG-RESISTANCE; T790M MUTATIONS; SUPPORTIVE CARE; C-MET;
D O I
10.3816/CLC.2009.n.039
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Most advanced non-small-cell lung cancers (NSCLCs) with activating epidermal growth factor receptor (EGFR) mutations (exon 19 deletions or L858R) initially respond to the EGFR tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib. However, over time (median of 6-12 months), most tumors develop acquired resistance to EGFR TKIs. Intense research in these NSCLCs has identified two major mechanisms of resistance to gefitinib/erlotinib: secondary resistance mutations and "oncogene kinase switch" systems. The secondary T790M mutation occurs in 50% of EGFR-mutated patients with TKI resistance, and in vitro, this mutation negates the hypersensitivity of activating EGFR mutations. Sensitive detection methods have identified a proportion of TKI-naive tumors that carry T790M, and these resistant clones may be selected after exposure to gefitinib or erlotinib. Other secondary resistance mutations (D761Y, L747S, T854A) seem to be rare. The amplification of the MET oncogene is present in 20% of TKI-resistant tumors; however, in half of the cases with this "oncogene kinase switch" mechanism the T790M is coexistent. It is possible that other kinases (such as insulin-like growth factor-1 receptor [IGF-1R]) might also be selected to bypass EGFR pathways in resistant tumors. The growing preclinical data in EGFR-mutated NSCLCs with acquired resistance to gefitinib or erlotinib has spawned the initiation or conception of clinical trials testing novel EGFR inhibitors that in vitro inhibit T790M (neratinib, XL647, BIBW 2992, and PF-00299804), MET, or IGF-1R inhibitors in combination with EGFR TKIs, and heat shock protein 90 inhibitors. Ongoing preclinical and clinical research in EGFR-mutated NSCLC has the potential to significantly improve the outcomes of patients with these somatic mutations.
引用
收藏
页码:281 / 289
页数:9
相关论文
共 94 条
  • [91] Yang C, 2008, J CLIN ONCOL S, V26, pS430
  • [92] Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer
    Yokouchi, Hiroshi
    Yamazaki, Koichi
    Kinoshita, Ichiro
    Konishi, Jun
    Asahina, Hajime
    Sukoh, Noriaki
    Harada, Masao
    Akie, Kenji
    Ogura, Shigeaki
    Ishida, Takashi
    Munakata, Mitsuru
    Dosaka-Akita, Hirotoshi
    Isobe, Hiroshi
    Nishimura, Masaharu
    [J]. BMC CANCER, 2007, 7 (1)
  • [93] Prospective validation for prediction of gefitinib sensitivity by epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer
    Yoshida, Kimihide
    Yatabe, Yasushi
    Park, Ji Young
    Shimizu, Junichi
    Horio, Yoshitsugu
    Matsuo, Keitaro
    Kosaka, Takayuki
    Mitsudomi, Tetsuya
    Hida, Toyoaki
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (01) : 22 - 28
  • [94] The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
    Yun, Cai-Hong
    Mengwasser, Kristen E.
    Toms, Angela V.
    Woo, Michele S.
    Greulich, Heidi
    Wong, Kwok-Kin
    Meyerson, Matthew
    Eck, Michael J.
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2008, 105 (06) : 2070 - 2075